Skip to Content

SHARE

Clinical Trials Details

Central Nervous System Metastatis

DTI_002, Intravenous 4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC_PEN) in malignancies involving the Central Nervous System

Objective

This phase II study is for patients with metastatic disease involving the Central Nervous System (CNS) who no other standard treatment options are available. The focus is on melanoma, breast, lung and primary CNS cancers.

IRB Protocol Number
DTI-022
Principal Investigator(s)
Roger Santala, MD
Contact
Susan Dillon, RN BSN OCN at 406-435-7443
or sdillon1@billingsclinic.org

Location

  • Billings Clinic Hospital Fountain Courtyard - South of the Hospital Cafeteria
    2750 9th Ave North
    Billings, MT 59101